Mechanism and Treatment of Inflammatory Bowel Disease with Mesalamine

Primary Mechanism of Action and Formulations

The European Society of Gastrointestinal Endoscopy recommends mesalamine suppositories for proctitis (rectal inflammation) and enemas for left-sided colitis, with oral delayed-release formulations for more extensive disease 1, 2
Different formulations of mesalamine target specific areas of inflammation, including suppositories, enemas, and oral delayed-release formulations, allowing for tailored treatment based on disease location and severity 1, 3, 4

For mild to moderate ulcerative colitis, the American Gastroenterological Association recommends topical mesalamine 1g daily combined with oral mesalamine 2-4g daily as effective first-line therapy 1, 3
The European Crohn’s and Colitis Organisation suggests that topical mesalamine is more effective than topical corticosteroids for treating distal ulcerative colitis 1, 2
For Crohn's disease, the American Gastroenterological Association recommends high-dose mesalamine (4g daily) as sufficient initial therapy for mild ileocolonic disease 5, 6

The American College of Gastroenterology recommends standard dosing for oral mesalamine ranges from 2-3g daily, with high-dose therapy defined as >3g daily 4
Combination therapy (oral plus topical) is more effective than either treatment alone for distal disease, according to the European Society of Gastrointestinal Endoscopy 1, 2
For maintenance therapy, the American Gastroenterological Association recommends standard-dose mesalamine is superior to low-dose for preventing relapse 4

The National Institute for Health and Care Excellence states that mesalamine is generally well-tolerated with fewer side effects than sulfasalazine, with common adverse effects including perianal irritation and gastrointestinal upset 1
Rare but serious adverse effects that require monitoring include worsening of colitis, interstitial pneumonitis, and nephritis, which are mostly reversible with cessation of therapy 1